Search results for "CERAMIDE"

showing 10 items of 94 documents

GIPC: Glycosyl Inositol Phospho Ceramides, the major sphingolipids on earth

2016

What are the most abundant sphingolipids on earth? The answer is Glycosyl Inositol Phosphoryl Ceramides (GIPCs) present in fungi and the green lineage. In this review, we discuss the putative role of plant GIPCs in the lipid bilayer asymmetry, in the lateral organization of membrane rafts and in the very long chain fatty acid inter-leaflet coupling of lipids in the plant plasma membrane (PM). A special focus on the structural similarities -and putative functions- of GIPCs is discussed by comparison with animal gangliosides, structural homologs of plant GIPCs.

0106 biological sciences0301 basic medicineGlycosylationGlycosylationVery long chain fatty acidPlant ScienceBiologyCeramidesModels Biological01 natural sciencesCell wall03 medical and health scienceschemistry.chemical_compoundMembrane MicrodomainsPlant defense against herbivoryAnimalsGlycosylInositolLipid bilayerSphingolipidsMini-ReviewPlantsSphingolipid030104 developmental biologychemistryBiochemistrylipids (amino acids peptides and proteins)010606 plant biology & botanyPlant Signaling & Behavior
researchProduct

Sphingolipids and Inositol Phosphates Regulate the Tau Protein Phosphorylation Status in Humanized Yeast

2020

Hyperphosphorylation of protein tau is a hallmark of Alzheimer’s disease (AD). Changes in energy and lipid metabolism have been correlated with the late onset of this neurological disorder. However, it is uncertain if metabolic dysregulation is a consequence of AD or one of the initiating factors of AD pathophysiology. Also, it is unclear whether variations in lipid metabolism regulate the phosphorylation state of tau. Here, we show that in humanized yeast, tau hyperphosphorylation is stimulated by glucose starvation in coincidence with the downregulation of Pho85, the yeast ortholog of CDK5. Changes in inositol phosphate (IP) signaling, which has a central role in energy metabolism, altere…

0301 basic medicineCDK5Cèl·lulesTau proteinSit42HyperphosphorylationSaccharomyces cerevisiaeSACCHAROMYCES-CEREVISIAECeramide03 medical and health scienceschemistry.chemical_compoundCell and Developmental Biology0302 clinical medicineInositolceramideYpk1Inositol phosphatelcsh:QH301-705.51-IP7Original Researchchemistry.chemical_classificationScience & TechnologybiologyChemistryKinaseNEURODEGENERATIONLipid metabolismCell BiologyProtein phosphatase 2Fpk1MICROTUBULE-BINDINGPho85SERINE PALMITOYLTRANSFERASECell biologyALZHEIMERS-DISEASE030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesisGLYCOGEN-SYNTHASE KINASE-3-BETAbiology.proteinKINASE-ACTIVITYPhosphorylationLife Sciences & BiomedicineBETA TOXICITYProteïnesDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

The Influence of Hydrogen Bonding on Sphingomyelin/Colipid Interactions in Bilayer Membranes

2016

The phospholipid acyl chain composition and order, the hydrogen bonding, and properties of the phospholipid headgroup all influence cholesterol/phospholipid interactions in hydrated bilayers. In this study, we examined the influence of hydrogen bonding on sphingomyelin (SM) colipid interactions in fluid uni- and multilamellar vesicles. We have compared the properties of oleoyl or palmitoyl SM with comparable dihydro-SMs, because the hydrogen bonding properties of SM and dihydro-SM differ. The association of cholestatrienol, a fluorescent cholesterol analog, with oleoyl sphingomyelin (OSM) was significantly stronger than its association with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, …

0301 basic medicineCeramideDouble bondStereochemistryLipid BilayersBiophysicsPhospholipidOleic AcidsPalmitic AcidsCholesterol analogCeramides03 medical and health scienceschemistry.chemical_compoundLipid bilayerchemistry.chemical_classificationMembranesHydrogen bondBilayerfungita1182technology industry and agricultureHydrogen BondingSphingomyelins030104 developmental biologychemistrylipids (amino acids peptides and proteins)Sphingomyelin
researchProduct

Acid sphingomyelinase – a regulator of canonical transient receptor potential channel 6 (TRPC6) activity

2019

Recent investigations propose the acid sphingomyelinase (ASM)/ceramide system as a novel target for antidepressant action. ASM catalyzes the breakdown of the abundant membrane lipid sphingomyelin to the lipid messenger ceramide. This ASM‐induced lipid modification induces a local shift in membrane properties, which influences receptor clustering and downstream signaling. Canonical transient receptor potential channels 6 (TRPC6) are non‐selective cation channels located in the cell membrane that play an important role in dendritic growth, synaptic plasticity and cognition in the brain. They can be activated by hyperforin, an ingredient of the herbal remedy St. John’s wort for treatment of de…

0301 basic medicineCeramideMedizinCeramidesPC12 CellsBiochemistryFIASMATRPC603 medical and health sciencesCellular and Molecular NeuroscienceTransient receptor potential channelchemistry.chemical_compound0302 clinical medicineddc:570medicineAnimalsInstitut für Biochemie und BiologieIon channelTRPC Cation ChannelsNeuronsRatsCell biologySphingomyelin Phosphodiesterase030104 developmental biologychemistryLipid modificationAcid sphingomyelinaseSphingomyelin030217 neurology & neurosurgerymedicine.drugJournal of Neurochemistry
researchProduct

Genetics and Gene Therapy of Anderson-Fabry Disease.

2018

Fabry's disease is a genetic disorder of X-linked inheritance caused by mutations in the alpha galactosidase A gene resulting in deficiency of this lysosomal enzyme. The progressive accumulation of glycosphingolipids, caused by the inadequate enzymatic activity, is responsible of organ dysfunction and thus of clinical manifestations. In the presence of a high clinical suspicion, a careful physical examination and specific laboratory tests are required, finally diagnosis of Fabry's disease is confirmed by the demonstration of absence or reduced alpha-galactosidase A enzyme activity in hemizygous men and gene typing in heterozygous females; in fact the performance of enzymatic activity assay …

0301 basic medicineGenetic enhancementChaperone therapyDisease030204 cardiovascular system & hematologyBioinformaticsMice0302 clinical medicineAlpha galactosidase ADrug DiscoveryGenetics (clinical)KidneybiologyTrihexosylceramidesGenetic disorderEnzyme replacement therapyDependovirusRecombinant ProteinsAlpha galactosidase A; Chaperone therapy; Enzyme replacement therapy; Fabry disease; Gene therapy; Viral vectors; Molecular Medicine; Molecular Biology; Genetics; Drug Discovery3003 Pharmaceutical Science; Genetics (clinical)Isoenzymesmedicine.anatomical_structureMolecular Medicinemedicine.symptomGenetic Vectors03 medical and health sciencesGene therapyViral vectorRare DiseasesGeneticGeneticsmedicineAnimalsHumansEnzyme Replacement TherapyMolecular BiologyAlpha-galactosidasebusiness.industryDrug Discovery3003 Pharmaceutical ScienceOrgan dysfunctionGenetic Therapymedicine.diseaseFabry diseaseDisease Models Animal030104 developmental biologyalpha-GalactosidaseMutationbiology.proteinFabry DiseasebusinessBiomarkersCurrent gene therapy
researchProduct

FragClust and TestClust, two informatics tools for chemical structure hierarchical clustering analysis applied to lipidomics. The example of Alzheime…

2016

Lipidomic analysis is able to measure simultaneously thousands of compounds belonging to a few lipid classes. In each lipid class, compounds differ only by the acyl radical, ranging between C10:0 (capric acid) and C24:0 (lignoceric acid). Although some metabolites have a peculiar pathological role, more often compounds belonging to a single lipid class exert the same biological effect. Here, we present a lipidomics workflow that extracts the tandem mass spectrometry data from individual files and uses them to group compounds into structurally homogeneous clusters by chemical structure hierarchical clustering analysis (CHCA). The case-to-control peak area ratios of the metabolites are then a…

0301 basic medicineHigh-resolution mass spectrometrySettore MED/09 - Medicina InternaChemical structureComputational biologyPlasma biomarkers01 natural sciencesTriglycerideBiochemistryHomogeneous clustersAnalytical ChemistryCeramide03 medical and health sciencesAlzheimer DiseaseTandem Mass SpectrometryHealth informatics toolsLipidomicsHumansStatistical analysisData miningChromatography High Pressure LiquidAgedAged 80 and overMolecular StructureChemistry010401 analytical chemistryLipids0104 chemical sciencesHierarchical clusteringPhospholipid030104 developmental biologyWorkflowBiochemistryCase-Control StudiesSettore MED/26 - Neurologia
researchProduct

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

2021

International audience; Background: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD.Methods and findings: A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi methodology. 35 FD clinical experts from 4 continents, representing 3389 FD patients, participated in 3 rounds of Delphi p…

0301 basic medicineMaleDelphi TechniqueEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Delphi methodDisease030105 genetics & heredityKidneyBiochemistry0302 clinical medicineEndocrinologyClinical outcomesClinical Trials as TopicGlobosidesTrihexosylceramidesMiddle Aged3. Good healthClinical trialIsoenzymesTreatment OutcomeInclusion and exclusion criteriaSecondary Outcome MeasureFemaleAdultmedicine.medical_specialtyConsensusLysosomal storage disorders03 medical and health sciencesQuality of life (healthcare)Inherited metabolic disordersGeneticsmedicineHumansEnzyme Replacement TherapyIntensive care medicineMolecular BiologyFabry diseaseSphingolipidsbusiness.industryClinical study designmedicine.diseaseFabry diseaseClinical trialDelphi consensusalpha-GalactosidaseQuality of LifeFabry DiseaseGlycolipidsbusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct

Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.

2019

Abstract Background Fabry disease is a rare, X-linked, lifelong progressive lysosomal storage disorder. Severely deficient α-galactosidase A activity in males is associated with the classic phenotype with early-onset, multisystem manifestations evolving to vital organ complications during adulthood. We assessed the ability of 2 low-dose agalsidase beta regimens to lower skin, plasma, and urine globotriaosylceramide (GL-3) levels, and influence clinical manifestations in male pediatric Fabry patients. Methods In this multicenter, open-label, parallel-group, phase 3b study, male patients aged 5–18 years were randomized to receive agalsidase beta at 0.5 mg/kg 2-weekly (n = 16) or 1.0 mg/kg 4-w…

0301 basic medicineMalemedicine.medical_specialtyAbdominal painAdolescentEndocrinology Diabetes and MetabolismGlobotriaosylceramideUrologyRenal function030105 genetics & heredityBiochemistrylaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRandomized controlled triallawBiopsyGeneticsmedicineHumansEnzyme Replacement TherapyChildMolecular BiologySkinKidneymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryTrihexosylceramidesEnzyme replacement therapymedicine.diseaseFabry diseaseIsoenzymesmedicine.anatomical_structureTreatment OutcomechemistryChild Preschoolalpha-GalactosidaseFabry Diseasemedicine.symptombusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct

Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group

2017

Fabry disease (FD) [OMIM 301500] is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A, resulting in progressive multisystem accumulation of globotriaosylceramide (Gb3). Although the introduction of Enzyme Replacement Therapy (ERT) resulted in a variety of clinical benefits, life-long intravenous (IV) treatment with ERT with an every other week schedule, may interfere with daily life activities and impact on QoL. We report here a multicentric, observational, longitudinal data analysis on a large cohort of 85 Italian FD patients (45 males, 40 females) from 11 out of 20 Italian regions, who received a cumulative number of 4269 home infu…

0301 basic medicinePediatricsmedicine.medical_specialtyQoLGlobotriaosylceramide03 medical and health scienceschemistry.chemical_compoundCollaborative group0302 clinical medicineEndocrinologyDisease severityGeneticGeneticsMedicine030212 general & internal medicinelcsh:QH301-705.5Molecular Biologylcsh:R5-920Fabry diseasebusiness.industrySettore BIO/14Home treatmentEnzyme replacement therapyAdherence; Enzyme replacement therapy; Fabry disease; Home treatment; QoLmedicine.diseaseFabry disease3. Good health030104 developmental biologylcsh:Biology (General)chemistryAdherenceEnzyme replacement therapyCohortarticle;congenital malformation; Fabry disease; enzyme replacement therapy; home treatment ; adherence; QoLObservational studyHome treatmentlcsh:Medicine (General)businessResearch Paper
researchProduct

The janus face of NKT cell function in autoimmunity and infectious diseases

2018

Natural killer T cells (NKT) are a subset of T lymphocytes bridging innate and adaptive immunity. These cells recognize self and microbial glycolipids bound to non-polymorphic and highly conserved CD1d molecules. Three NKT cell subsets, type I, II and NKT-like expressing different antigen receptors (TCR) were described and TCR activation promotes intracellular events leading to specific functional activities. NKT can exhibit different functions depending on the secretion of soluble molecules and the interaction with other cell types. NKT cells act as regulatory cells in the defence against infections but, on the other hand, their effector functions can be involved in the pathogenesis of sev…

0301 basic medicineglycolipidsAutoimmunityReviewAdaptive Immunitymedicine.disease_causeAutoimmunityCatalysiimmunologylcsh:Chemistry0302 clinical medicineT-Lymphocyte Subsetslcsh:QH301-705.5SpectroscopyInnate lymphoid cellhemic and immune systemsComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineNKTNatural killer T cellAcquired immune systemComputer Science ApplicationsCell biologyCD1DmicrobesCell typechemical and pharmacologic phenomenaGlycolipidBiologyCD1dCommunicable DiseasesCatalysisInorganic Chemistry03 medical and health sciencesmedicineAnimalsHumansMicrobePhysical and Theoretical ChemistryMolecular BiologyInflammationT-cell receptorOrganic ChemistryModels ImmunologicalAlpha-galactosylceramideAlpha-galactosylceramide; Autoimmunity; CD1d; Glycolipids; Microbes; NKT; Sulfatide; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryImmunity InnateSettore MED/16 - Reumatologia030104 developmental biologylcsh:Biology (General)lcsh:QD1-999biology.proteinNatural Killer T-CellsSulfatideCD8030215 immunology
researchProduct